Suven Life Sciences Ltd. (BSE: 530239) is a Hyderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹8,583 Cr, it ranks #641 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 10 in Life Sciences Tools and Services. At ₹261.35 (as of 25 Oct 2026), the share price is 35.2% below its 52-week high of ₹403.35 and 110.6% above its 52-week low of ₹124.11. The share price is up 30.6% over one year and down 17.3% over three months.
| Current Price | ₹261.35 |
|---|---|
| Market Cap | ₹8,583 Cr |
| BSE Code | 530239 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | -24 |
| Return on Equity | -78.80% |
| Return on Assets | -47.69% |
| 52-Week Range | ₹124.11 – ₹403.35 |
| 1-Year Price Change | +30.6% |
| 3-Month Price Change | -17.3% |
| Beta (1Y) | 0.82 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.suven.com |
| Revenue | ₹4 Cr |
|---|---|
| Net Profit | ₹-128 Cr |
| Net Margin | -3574.5% |
| EPS (Basic) | ₹-4.84 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D
1. Research and Development Services-This segment provides a range of drug discovery and development support services to pharma and biotech companies. 2. Manufacturing (CRAMS)-This segment develops and produces bulk drugs and intermediates under contract manufacturing services. 3. Services (DDDSS)-This segment offers clinical trials, testing, and analysis services, as well as engages in the collaborative research projects. 4. Unallocated-0
1. Research and Development Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,413 Cr | 35.2 | 13.94% | ₹1,063 Cr | +5.9% |
| Suven Life Sciences Ltd. | ₹8,583 Cr | -24 | -78.80% | ₹4 Cr | +30.6% |
| Vimta Labs Ltd | ₹2,338 Cr | 29.3 | 18.55% | ₹109 Cr | -32.5% |
| Tarsons Products Limited | ₹1,762 Cr | 117.2 | 2.26% | ₹110 Cr | +3.3% |
| Bilcare Ltd. | ₹224 Cr | 122.4 | -5.21% | — | — |
| Brooks Laboratories Ltd. | ₹199 Cr | 8.1 | 22.28% | ₹23 Cr | -53.0% |
| Jeevan Scientific Technology Ltd | ₹178 Cr | 130.4 | 1.68% | — | +34.0% |
| Vivo Bio Tech Ltd. | ₹31 Cr | -16.6 | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹28 Cr | -2.8 | -68.79% | — | -32.7% |
Listed by market capitalisation. Ratios are shown for context only.
Suven Life Sciences Ltd. is trading at ₹261.35, with a market capitalisation of ₹8,583 Cr.
Suven Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Suven Life Sciences Ltd. has a P/E of -24 and a return on equity of -78.80%.
Suven Life Sciences Ltd. is listed on the BSE under the scrip code 530239.
Suven Life Sciences Ltd.'s share price is up 30.6% over one year and down 17.3% over three months. Its 52-week range is ₹124.11 to ₹403.35.
In Q1 FY27, Suven Life Sciences Ltd. reported revenue of ₹4 Cr and net profit of ₹-128 Cr, with basic EPS of ₹-4.84 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.